Key result
Reduced apixaban lead-in dosing following parenteral treatment of acute venous thromboembolism did not result in higher rates of recurrent VTE or bleeding compared to full dosing.
Why the study?
There are limited data on the use of a reduced apixaban lead-in strategy following parenteral treatment of acute venous thromboembolism.
Does reduced apixaban lead-in dosing prevent recurrent venous thromboembolism or bleeding in patients with acute venous thromboembolism following parenteral treatment?
Does reduced apixaban lead-in dosing prevent recurrent venous thromboembolism or bleeding in patients with acute venous thromboembolism following parenteral treatment?
A reduced apixaban lead-in dosing strategy following parenteral treatment for acute VTE did not result in higher rates of recurrent VTE or bleeding compared to full dosing.
Should not yet change apixaban lead-in practice in acute VTE; leaves open need for randomized confirmation of reduced dosing.
• Limited data on use of a reduced apixaban lead-in strategy • Single-centered retrospective study at a large academic medical center • Patients who received reduced lead-in had higher baseline bleeding risk factors • Reduced lead-in did not have higher recurrent venous thromboembolism or bleeding
No takes yet. Share an insight, caveat, or question.
Veloria et al. (2025) studied this question. Reduced apixaban lead-in dosing following parenteral treatment of acute venous thromboembolism did not result in higher rates of recurrent VTE or bleeding compared to full dosing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: